Treatment Review No. 13; August 1994

HPV warts are a common but usually benign problem. However, some types of HPV have been linked to the development of cervical cancer. The company that makes HPMPC has begun testing the drug in Phase I and II clinical trials, which focus on safety and effectiveness.

A trial in New York is studying topical HPMPC for herpes simplex, another viral infection. You must have acyclovir resistant herpes to participate in this trial. The trial runs for 5 days. Participants are divided into two groups. One group will be treated with HPMPC ointment in different doses. The other group will be treated with placebo. Neither the participant nor the doctor will know which treatment is being given. After two weeks, all participants will be eligible to receive the drug. You may not take any other treatment for herpes while on the trial.

Intravenous HPMPC is also being studied for the treatment of CMV retinitis, a viral infection that can damage the eyes. Intravenous HPMPC has serious kidney toxicities. Kidney toxicities may be reduced by adjusting dosages and adding a drug called probenicid, which reduces the amount of HPMPC absorbed by the kidneys. Call The Network if you would like more information about these studies.

940801
ATR01307

Copyright © 1994 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org  http://206.179.124.69/network/index.html